Chromosome, I have a DCF model using a 10% discount rate, assuming we lose the Hikma case and the US limps out, Europe maxes out at $700mm (we always though over a billion since Omacor did that), and RoW does "ok". If you assume an acquiror could take out half the operating expenses (one drug added to US cardio sales force, c-suite gone, utilizing current research and legal talent internally), I get a stock price of just over $100.
This is a reasonable worst case scenario. Only this management team could have this thing trading at $15.
Market Data 
Markets 
AI
